Thu. 9 May 2024, 9:06am ET
Benzinga
Earnings, Earnings Beats, Earnings Misses, News
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.24) by 37.5 percent. This is a 89.86 percent increase over losses of $(1.48) per share from the same period last year. The company reported quarterly sales of $98.00 thousand which missed the analyst consensus estimate of $100.00 thousand by 2.00 percent. This is a 1.01 percent decrease over sales of $99.00 thousand the same period last year.